Search

Your search keyword '"Feng, F.Y."' showing total 319 results
Start Over Author "Feng, F.Y."
319 results on '"Feng, F.Y."'

1. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Author

Helzer, K.T., Sharifi, M.N., Sperger, J.M., Shi, Y., Annala, M., Bootsma, M.L., Reese, S.R., Taylor, A., Kaufmann, K.R., Krause, H.K., Schehr, J.L., Sethakorn, N., Kosoff, D., Kyriakopoulos, C., Burkard, M.E., Rydzewski, N.R., Yu, M., Harari, P.M., Bassetti, M., Blitzer, G., Floberg, J., Sjöström, M., Quigley, D.A., Dehm, S.M., Armstrong, A.J., Beltran, H., McKay, R.R., Feng, F.Y., O’Regan, R., Wisinski, K.B., Emamekhoo, H., Wyatt, A.W., Lang, J.M., and Zhao, S.G.

Published
2023
Full Text
View/download PDF

4. International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy

Author

Berlin, A., Moraes, F.Y., Sanmamed, N., Glicksman, R., Koven, A., Espin-Garcia, O., Leite, E.T.T., Silva, J.L.F., Gadia, R., Nesbitt, M., Catton, C.N., Kaffenberger, S., Salami, S.S., Morgan, T.M., Hearn, J.W.D., Jackson, W.C., Mehra, R., Chung, P., Fleshner, N.E., Zumsteg, Z.S., Dess, R.T., Feng, F.Y., Finelli, A., and Spratt, D.E.

Published
2018
Full Text
View/download PDF

5. Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Hakansson, A., additional, Van der Eecken, K., additional, Song, Y., additional, Liu, Y., additional, Fonteyne, V., additional, Verbeke, S., additional, Song, D., additional, Ross, A.E., additional, Feng, F.Y., additional, Gillessen, S., additional, Attard, G., additional, James, N., additional, Lotan, T.L., additional, Davicioni, E., additional, Sweeney, C., additional, Tran, P.T., additional, Deek, M.P., additional, and Ost, P., additional

Published
2023
Full Text
View/download PDF

6. Prospective Characterization of Circulating Tumor Cells in Hormone Sensitive Oligometastatic Prostate Cancer Patients on a Metastasis-Directed Therapy Trial

Author

Bazyar, S., primary, Sutera, P., additional, Phillips, R., additional, Deek, M.P., additional, Radwan, N., additional, Marshall, C.H., additional, Mishra, M.V., additional, Rana, Z.H., additional, Molitoris, J.K., additional, Kwok, Y., additional, Gupta, S., additional, Wenstrup, R., additional, DeWeese, T.L., additional, Song, D., additional, Feng, F.Y., additional, Pienta, K., additional, Antonarakis, E., additional, Kiess, A.P., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

8. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)

Author

Nguyen, P.L., primary, Kollmeier, M.A., additional, Rathkopf, D., additional, Hoffman, K.E., additional, Zurita-Saavedra, A., additional, Spratt, D.E., additional, Dess, R.T., additional, Liauw, S., additional, Szmulewitz, R., additional, Einstein, D.J., additional, Bubley, G., additional, Yu, J.B., additional, An, Y., additional, Wong, A.C., additional, Feng, F.Y., additional, Mckay, R.R., additional, Rose, B.S., additional, Shin, K.Y., additional, Kibel, A., additional, and Taplin, M.E.A., additional

Published
2023
Full Text
View/download PDF

9. Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712

Author

Deek, M.P., primary, Shetty, A., additional, Song, Y., additional, Efstathiou, J.A., additional, Feng, F.Y., additional, Shipley, W.U., additional, Simko, J., additional, Mouw, K.W., additional, Miyamoto, D.T., additional, Pollack, A., additional, Michaelson, D., additional, Zietman, A.L., additional, Coen, J.J., additional, Dahl, D.M., additional, Jani, A., additional, Souhami, L., additional, Chang, B.K., additional, Lee, R.J., additional, Rodgers, J., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

10. Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Song, Y., additional, Hodges, T., additional, Hoang, T., additional, Rana, Z.H., additional, Pienta, K., additional, Feng, F.Y., additional, Song, D., additional, DeWeese, T.L., additional, Gillessen, S., additional, James, N., additional, Attard, G., additional, Deek, M.P., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

11. Impact of Testosterone Recovery on Clinical Outcomes of Patients Treated with Salvage Radiotherapy and Androgen Suppression: A Secondary Analysis of the NRG/RTOG 0534 Sport Phase 3 Trial

Author

Pra, A. Dal, primary, Lyness, J., additional, Pollack, A., additional, Tran, P.T., additional, Koontz, B.F., additional, Abramowitz, M.C., additional, Mahal, B.A., additional, Martin, A.G., additional, Michalski, J.M., additional, Balogh, A., additional, Lukka, H., additional, Faria, S.L., additional, Rodrigues, G., additional, Beauchemin, M.C., additional, Lee, R.J., additional, Seaward, S.A., additional, Coen, S.D., additional, Allen, A.M., additional, Pugh, S., additional, and Feng, F.Y., additional

Published
2023
Full Text
View/download PDF

12. Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

Author

Phillips, R., primary, Proudfoot, J., additional, Davicioni, E., additional, Spratt, D.E., additional, Feng, F.Y., additional, Simko, J., additional, Den, R.B., additional, Pollack, A., additional, Rosenthal, S.A., additional, Sartor, O., additional, Sweeney, C., additional, Attard, G., additional, Patel, S.I., additional, Hall, W.A., additional, Efstathiou, J.A., additional, Shah, A.B., additional, Hoffman, K.E., additional, Pugh, S., additional, Sandler, H.M., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

15. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A. and Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A.

Abstract

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic an

Published
2023

16. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ngozi Ekeke, O. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C.J. Mahal, B.A. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Pablo Sade, J. Sartor, O.A. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A. and Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ngozi Ekeke, O. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C.J. Mahal, B.A. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Pablo Sade, J. Sartor, O.A. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A.

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

17. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.

Abstract

Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

20. Machine Learning for the Prediction of Distant Metastases Following Postprostatectomy Salvage Radiation Therapy

Author

Sabbagh, A., primary, Tilki, D., additional, Feng, J., additional, Hong, J.C., additional, Chen, M.H., additional, Wu, J., additional, Huland, H., additional, Graefen, M., additional, Wiegel, T., additional, Böhmer, D., additional, Washington, S., additional, Cowan, J., additional, Cooperberg, M.R., additional, Feng, F.Y., additional, Carroll, P., additional, Trock, B., additional, Partin, A.W., additional, DAmico, A.V., additional, and Mohamad, O., additional

Published
2022
Full Text
View/download PDF

21. Machine Learning for the Prediction of Lymph Node Metastasis in Patients with Prostate Cancer

Author

Sabbagh, A., primary, III, S. Washington, additional, Tilki, D., additional, Hong, J.C., additional, Feng, J., additional, Chen, M.H., additional, Wu, J., additional, Huland, H., additional, Graefen, M., additional, Wiegel, T., additional, Böhmer, D., additional, Cowan, J., additional, Cooperberg, M.R., additional, Feng, F.Y., additional, Trock, B., additional, Partin, A.W., additional, DAmico, A.V., additional, Carroll, P., additional, and Mohamad, O., additional

Published
2022
Full Text
View/download PDF

22. Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC)

Author

Sandler, H.M., primary, Shore, N., additional, Dearnaley, D., additional, Freedland, S.J., additional, Smith, M.R., additional, Rosales, R., additional, Brookman-May, S.D., additional, Dicker, A.P., additional, McKenzie, M.R., additional, Bossi, A., additional, Widmark, A., additional, Wiegel, T., additional, Martin, J., additional, Miladinovic, B., additional, Lefresne, F., additional, Ciprotti, M., additional, McCarthy, S.A., additional, Mundle, S.D., additional, Tombal, B.F., additional, and Feng, F.Y., additional

Published
2022
Full Text
View/download PDF

23. The Influence of Pelvic Lymph Node Dissection Volumes on Clinical Outcomes in NRG/RTOG 0534

Author

Hall, W.A., primary, Pugh, S., additional, Pollack, A., additional, Lawton, C.A.F., additional, Spratt, D.E., additional, Efstathiou, J.A., additional, Morgan, T.M., additional, Mckay, R.R., additional, Simko, J., additional, Martin, A.G., additional, Michalski, J.M., additional, Balogh, A., additional, Lukka, H., additional, Faria, S., additional, Hagerty, M., additional, Beauchemin, M.C., additional, Lee, R.J., additional, Seaward, S.A., additional, Seiferheld, W., additional, and Feng, F.Y., additional

Published
2022
Full Text
View/download PDF

24. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

Author

Sutera, P., primary, Deek, M.P., additional, Guler, O.C., additional, Hurmuz, P., additional, Reyhan, M., additional, Rowe, S., additional, Hrinivich, W.T., additional, Ren, L., additional, Song, D., additional, Kiess, A.P., additional, Oymak, E., additional, Pienta, K., additional, Pomper, M.G., additional, Feng, F.Y., additional, Ozyigit, G., additional, Tran, P.T., additional, Phillips, R., additional, and Onal, C., additional

Published
2022
Full Text
View/download PDF

25. INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients

Author

Singh, P., primary, Efstathiou, J.A., additional, Plets, M., additional, Jhavar, S.G., additional, Delacroix, S., additional, Tripathi, A., additional, Gupta, A., additional, Sachdev, S., additional, Jani, A., additional, Kirschner, A.N., additional, Tangen, C., additional, Bangs, R., additional, Joshi, M., additional, Costello, B.A., additional, Thompson, I.L., additional, Feng, F.Y., additional, and Lerner, S., additional

Published
2022
Full Text
View/download PDF

26. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology

Author

Tward, J.D., primary, Zhang, J., additional, Esteva, A., additional, Mohamad, O., additional, van der Wal, D., additional, Simko, J., additional, DeVries, S., additional, Huang, H.C., additional, Schaeffer, E.M., additional, Morgan, T.M., additional, Campbell, H.A., additional, Monson, J., additional, Wallace, J., additional, Ferguson, M.J., additional, Bahary, J.P., additional, Sandler, H.M., additional, Spratt, D.E., additional, Rodgers, J., additional, Feng, F.Y., additional, and Tran, P.T., additional

Published
2022
Full Text
View/download PDF

27. Efficacy of Bicalutamide Monotherapy in Prostate Cancer: A Network Meta-Analysis of 10 Randomized Trials

Author

Baydoun, A., primary, Sun, Y., additional, Sandler, H.M., additional, Bolla, M., additional, Nabid, A., additional, Denham, J.W., additional, Jia, A.Y., additional, Zaorsky, N.G., additional, Garcia, J., additional, Brown, J., additional, Jackson, W.C., additional, Dess, R.T., additional, Efstathiou, J.A., additional, Feng, F.Y., additional, Maingon, P., additional, Steigler, A., additional, Souhami, L., additional, Berlin, A., additional, Kishan, A.U., additional, and Spratt, D.E., additional

Published
2022
Full Text
View/download PDF

28. Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)

Author

Pra, A. Dal, primary, Zwahlen, D.R., additional, Liu, V.Y., additional, Hayoz, S., additional, Spratt, D.E., additional, Davicioni, E., additional, Liu, Y., additional, Proudfoot, J.A., additional, Schär, C., additional, Hölscher, T., additional, Gut, P., additional, Polat, B., additional, Hildebrandt, G., additional, Mueller, A.C., additional, Plasswilm, L., additional, Feng, F.Y., additional, Pollack, A., additional, Thalmann, G., additional, Aebersold, D.M., additional, and Ghadjar, P., additional

Published
2022
Full Text
View/download PDF

29. Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial

Author

Tran, P.T., primary, Lowe, K., additional, Wang, H., additional, Tsai, H.L., additional, Song, D., additional, Hung, A.Y., additional, Hearn, J.W.D., additional, Miller, S.R., additional, Lotan, T.L., additional, DeWeese, T.L., additional, Orton, M.D., additional, Jr, C. Deville, additional, Liauw, S., additional, Heath, E., additional, Greco, S.C., additional, Desai, N.B., additional, Spratt, D.E., additional, Feng, F.Y., additional, Beer, T., additional, and Antonarakis, E., additional

Published
2022
Full Text
View/download PDF

30. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A. and Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.

Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden

Published
2022

31. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (European Urology (2022) 82(1) (6–11), (S0302283822016505), (10.1016/j.eururo.2022.02.010))

Author

Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A. and Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A.

Abstract

The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained. The authors would like to apologise for any inconvenience caused. © 2022 The Author(s)

Published
2022

32. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden, National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022

33. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022

35. Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer

Author

Tran, P.T., primary, Berlin, A., additional, Siva, S., additional, Reynders, D., additional, Phillips, R., additional, Glicksman, R., additional, Foroudi, F., additional, Udovicich, C., additional, Fonteyne, V., additional, Deek, M.P., additional, Feng, F.Y., additional, Chung, P., additional, Murphy, D., additional, and Ost, P., additional

Published
2021
Full Text
View/download PDF

36. Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer

Author

Nguyen, P.L., primary, Huang, H.C., additional, Davicioni, E., additional, Sandler, H.M., additional, Shipley, W.U., additional, Efstathiou, J.A., additional, Simko, J., additional, Pollack, A., additional, Dicker, A.P., additional, Roach, M., additional, Rosenthal, S.A., additional, Morginstin, M., additional, Mendez, L., additional, Hartford, A.C., additional, Hall, W.A., additional, Desai, A.B., additional, Rabinovitch, R., additional, Peters, C.A., additional, Rodgers, J., additional, and Feng, F.Y., additional

Published
2021
Full Text
View/download PDF

37. Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials

Author

Kishan, A.U., primary, Romero, T., additional, Wang, X., additional, Pisansky, T.M., additional, Roach, M., additional, Bolla, M., additional, Steigler, A., additional, Denham, J.W., additional, Shipley, W.U., additional, Sandler, H.M., additional, Feng, F.Y., additional, Joseph, D.J., additional, Armstrong, J.G., additional, Dunne, M., additional, Malone, S., additional, Roy, S., additional, Zapatero, A., additional, Sun, Y., additional, Michalski, J.M., additional, and Spratt, D.E., additional

Published
2021
Full Text
View/download PDF

38. Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Author

McDonald, A.M., primary, DeMora, L., additional, Lenzie, A., additional, Hoyle, J., additional, Yang, E.S., additional, Michalski, J.M., additional, Parliament, M.B., additional, Bahary, J.P., additional, Hurwitz, M.D., additional, III, M.Roach, additional, Spratt, D.E., additional, Mishra, M.V., additional, Valicenti, R.K., additional, Lau, H., additional, Souhami, L., additional, Mendez, L., additional, Chen, Y., additional, Doncals, D.E., additional, Feng, F.Y., additional, and Sandler, H.M., additional

Published
2021
Full Text
View/download PDF

39. Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer

Author

Kishan, A.U., primary, Sun, Y., additional, Pisansky, T.M., additional, Bolla, M., additional, Steigler, A., additional, Denham, J.W., additional, Shipley, W.U., additional, Sandler, H.M., additional, Feng, F.Y., additional, Joseph, D.J., additional, Armstrong, J.G., additional, Dunne, M., additional, Zapatero, A., additional, Ma, T.M., additional, Romero, T., additional, Wang, X., additional, Steinberg, M.L., additional, Jackson, W.C., additional, Dess, R.T., additional, and Spratt, D.E., additional

Published
2021
Full Text
View/download PDF

40. Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer

Author

Dess, R.T., primary, Sun, Y., additional, Bolla, M., additional, Zapatero, A., additional, Malone, S., additional, Kishan, A.U., additional, Roy, S., additional, Jackson, W.C., additional, Lawton, C.A.F., additional, Sartor, O., additional, Nguyen, P.L., additional, Michalski, J.M., additional, Pisansky, T.M., additional, Roach, M., additional, Sandler, H.M., additional, Schipper, M., additional, Feng, F.Y., additional, and Spratt, D.E., additional

Published
2021
Full Text
View/download PDF

41. Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics

Author

Sutera, P., primary, Van der Eecken, K., additional, Kishan, A.U., additional, Hamid, A., additional, Grist, E., additional, Attard, G., additional, Lotan, T.L., additional, Mendes, A., additional, Sweeney, C., additional, Paller, C., additional, Carducci, M., additional, Ross, A.E., additional, Pienta, K., additional, Feng, F.Y., additional, Eisenberger, M., additional, Antonarakis, E.S., additional, Ost, P., additional, Tran, P.T., additional, and Deek, M.P., additional

Published
2021
Full Text
View/download PDF

42. NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

Author

Dahl, D.M., primary, Rodgers, J., additional, Shipley, W.U., additional, Michaelson, D., additional, Wu, C.L., additional, Parker, W., additional, Efstathiou, J.A., additional, Jani, A., additional, Cury, F., additional, Hudes, R., additional, Michalski, J.M., additional, Hartford, A.C., additional, Song, D., additional, Citrin, D.E., additional, Karrison, T.G., additional, and Feng, F.Y., additional

Published
2021
Full Text
View/download PDF

43. Utility of Long-Term Follow-Up to Determine Safety in Radiotherapy-Specific Trials for Localized Prostate Cancer: Meta-Analysis of 29 Randomized Trials

Author

Jaworski, E., primary, Fang, F., additional, Gharzai, L.A., additional, McFarlane, M., additional, Solanki, A.A., additional, Zaorsky, N.G., additional, Mahal, B.A., additional, Feng, F.Y., additional, Ponsky, L., additional, Garcia, J., additional, Fredman, E.T., additional, Guo, G., additional, Berlin, A., additional, Roy, S., additional, Jackson, W.C., additional, Dess, R.T., additional, Schipper, M., additional, and Spratt, D.E., additional

Published
2021
Full Text
View/download PDF

44. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

Author

Jackson, W.C., primary, Tang, M., additional, Schipper, M., additional, Sandler, H.M., additional, Zumsteg, Z.S., additional, Efstathiou, J.A., additional, Shipley, W.U., additional, Seiferheld, W., additional, Lukka, H., additional, Bahary, J.P., additional, Zietman, A.L., additional, Pisansky, T.M., additional, Zeitzer, K.L., additional, Hall, W.A., additional, Dess, R.T., additional, Lovett, R.D., additional, Balogh, A., additional, Feng, F.Y., additional, and Spratt, D.E., additional

Published
2020
Full Text
View/download PDF

46. The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)

Author

Hall, W.A., primary, Karrison, T.G., additional, Rosenthal, S.A., additional, Amin, M., additional, Gomella, L.G., additional, Purdy, J.A., additional, Sartor, O., additional, Michalski, J.M., additional, Garzotto, M., additional, Bergom, C., additional, Jani, A., additional, Lawton, C.A.F., additional, Simko, J., additional, Moore, J., additional, Gore, E.M., additional, Lee, W.R., additional, Nguyen, P.L., additional, Danielson, B.L., additional, Sandler, H.M., additional, and Feng, F.Y., additional

Published
2020
Full Text
View/download PDF

47. Clinical-Genomic Sub-classification of High-Risk Prostate Cancer: Implications for Tailoring Therapy and Clinical Trial Design

Author

Muralidhar, V., primary, Alshalalfa, M., additional, Spratt, D.E., additional, Liu, S., additional, Karnes, R.J., additional, Schaeffer, E.M., additional, Davicioni, E., additional, Feng, F.Y., additional, Klein, E.A., additional, Tosoian, J., additional, Berlin, A., additional, Den, R.B., additional, and Nguyen, P.L., additional

Published
2020
Full Text
View/download PDF

48. Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

Author

Spratt, D.E., primary, Malone, S., additional, Roy, S., additional, Grimes, S., additional, Eapen, L., additional, Morgan, S.C., additional, Malone, J., additional, Craig, J., additional, Dess, R.T., additional, Jackson, W.C., additional, Schipper, M., additional, Michalski, J.M., additional, Lee, W.R., additional, Pisansky, T.M., additional, Feng, F.Y., additional, Shipley, W.U., additional, Sandler, H.M., additional, Roach, M., additional, Sun, Y., additional, and Lawton, C.A.F., additional

Published
2020
Full Text
View/download PDF

49. Comprehensive Analysis of Candidate Surrogate Endpoints in Localized Prostate Cancer: Analysis of 59 Randomized Trials

Author

Gharzai, L.A., primary, Jiang, R., additional, Wallington, D.G., additional, Jones, G.P., additional, Birer, S., additional, Jairath, N.K., additional, Jaworski, E., additional, McFarlane, M., additional, Mahal, B.A., additional, Sandler, H.M., additional, Morgan, T.M., additional, Kishan, A.U., additional, Feng, F.Y., additional, Schipper, M., additional, Dess, R.T., additional, Jackson, W.C., additional, and Spratt, D.E., additional

Published
2020
Full Text
View/download PDF

50. Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408

Author

Mell, L.K., primary, Pugh, S., additional, Jones, C.U., additional, Nelson, T.J., additional, Morginstin, M., additional, Gore, E.M., additional, Zakeri, K., additional, Bahary, J.P., additional, Souhami, L., additional, Michalski, J.M., additional, Hartford, A.C., additional, Mishra, M.V., additional, Roach, M., additional, Parliament, M.B., additional, Choi, K.N., additional, Pisansky, T.M., additional, Husain, S.M., additional, Malone, S., additional, Horwitz, E.M., additional, and Feng, F.Y., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results